Background/Aims: This study is the first of its kind to examine the impact of the Ramadan fasting on hydration status, plasma brain natriuretic peptide (BNP) levels, and kidney function in chronic kidney disease (CKD) patient. Methods: This prospective cohort study included 2 groups of patients with CKD grades 2–4: thirty-one Muslim patients who fasted the month of Ramadan (fasting group) and 26 Muslim patients who did not fast (control group). One week before the Ramadan fast, in the last week of the month of Ramadan (4 weeks), and 4 weeks after the end of the Ramadan month (8 weeks), hydration status and blood analysis of urea, creatinine and BNP levels were measured. Results: Among fasting patients, serum urea levels increased significantly (p = 0.024) during the last week of fasting and returned to basal levels at 4 weeks after the end of the Ramadan month, the estimated glomerular filtration rate did not change significantly at the end of fasting (p = 0.411), the hydration status indices and plasma BNP levels were significantly decreased after fasting (p ≤ 0.021) but returned to basal values 4 weeks thereafter. Conclusions: Patients with CKD grades 2–4 can fast throughout the month of Ramadan with no significant deterioration of renal functions and with a reasonable degree of safety.

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047.
Azizi F: Islamic fasting and health. Ann Nutr Metab 2010; 56: 273–282.
Berbari AE, Daouk NA, Mallat SG, Jurjus AR: Ramadan fasting in health and disease; in Berbari AE, Mancia G (eds): Special Issues in Hypertension. Milan, Springer-Verlag, 2012, pp 331–346.
Khedmat H, Taheri S: Ramadan fasting and transplantation: current knowledge and what we still need to know. Saudi J Kidney Dis Transpl 2010; 21: 417–420.
Abdalla AH, Shaheen FA, Rassoul Z, Owda AK, Popovich WF, Mousa DH, al-Hawas F, al-Sulaiman MH, al-Khader AA: Effect of Ramadan fasting on Moslem kidney transplant recipients. Am J Nephrol 1998; 18: 101–104.
Boobes Y, Bernieh B, Al Hakim MR: Fasting Ramadan in kidney transplant patients is safe. Saudi J Kidney Dis Transpl 2009; 20: 198–200.
Bernieh BO, Mohamed AO, Wafa AM: Ramadan fasting and renal transplant recipients: Clinical and biochemical effects. Saudi J Kidney Dis Transpl 1994; 5: 470–473.
Einollahi B, Lessan-Pezeshki M, Pourfarziani V, Aghdam B, Rouzbeh J, Ghadiani MH, Nemati E: Ramadan fasting in kidney transplant recipients with normal renal function and with mild-to-moderate renal dysfunction. Int Urol Nephrol 2009; 41: 417–422.
Ghalib M, Qureshi J, Tamim H, Ghamdi G, Flaiw A, Hejaili F, Taher S, Katheri A, Shaheen F, Al-Khader AA: Does repeated Ramadan fasting adversely affect kidney function in renal transplant patients? Transplantation 2008; 85: 141–144.
Hejaili F, Qurashi S, Binsalih S, Jaradt M, Al Sayyari A: Effect of repeated Ramadan fasting in the hottest months of the year on renal graft function. Nephrourol Mon 2014; 6:e14362.
Qurashi S, Tamimi A, Jaradat M, Al Sayyari A: Effect of fasting for Ramadan on kidney graft function during the hottest month of the year (August) in Riyadh, Saudi Arabia. Exp Clin Transplant 2012; 10: 551–653.
Khedmat H, Taheri S: Ramadan fasting and transplantation: current knowledge and what we still need to know. Saudi J Kidney Dis Transpl 2010; 21: 417–420.
El-Wakil HS, Desoky I, Lotfy N, Adam AG: Fasting the month of Ramadan by Muslims: could it be injurious to their kidneys? Saudi J Kidney Dis Transpl 2007; 18: 349–354.
Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM: Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transpl 2010; 21: 898–902.
Mbarki H, Tazi N, Najdi A, Tachfouti N, Arrayhani M, Sqalli T: Effects of fasting during Ramadan on renal function of patients with chronic kidney disease. Saudi J Kidney Dis Transpl. 2015; 26: 320–324.
Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574–1579.
Crepaldi C, Lamas EI, Martino FK, Rodighiero MP, Scalzotto E, Wojewodzka-Zelezniakowicz M, Rosner MH, Ronco C: Bioimpedance and brain natriuretic peptide in peritoneal dialysis patients. Contrib Nephrol 2012; 178: 174–181.
Wabel P, Chamney P, Moissl U, Jirka T: Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif 2009; 27: 75–80.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
Bragazzi NL: Ramadan fasting and chronic kidney disease: does estimated glomerular filtration rate change after and before -Ramadan? Insights from a mini meta-analysis. Int J Nephrol Renovasc Dis 2015; 8: 53–57.
Al Wakeel J, Mitwalli AH, Alsuwaida A, Al Ghonaim M, Usama S, Hayat A, Shah IH: Recommendations for fasting in Ramadan for patients on peritoneal dialysis. Perit Dial Int 2013; 33: 86–91.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.